-+ 0.00%
-+ 0.00%
-+ 0.00%

Incyte partners with Bristol Myers Squibb on pancreatic cancer combination trial

PUBT·10/26/2026 13:49:13
Incyte partners with Bristol Myers Squibb on pancreatic cancer combination trial
  • Incyte announced new clinical trial collaborations with Bristol Myers Squibb and Synnovation to evaluate INCB161734 combinations in pancreatic ductal adenocarcinoma.
  • A Phase 1b trial will test INCB161734 with Bristol Myers Squibb's navlimetostat, an MTA-cooperative PRMT5 inhibitor, in advanced or metastatic disease.
  • A separate planned Phase 1b trial will evaluate INCB161734 with Synnovation's SNV1521, a PARP1 inhibitor, in advanced or metastatic disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202610260945BIZWIRE_USPR_____20261026_BW987057) on October 26, 2026, and is solely responsible for the information contained therein.